Aarti Pharmalabs Financial Integrity Audit
₹955.05-2.05%
- Market cap
- ₹8,658 crore
- P/E
- 40.6
- P/B
- 4.08
- ROE
- 8.5%
- Dividend yield
- 0.21%
Aarti Pharmalabs shows a Healthy financial integrity status with 0 flagged accounting items.
Aarti Pharmalabs accounting & financial health audit
Automated forensic signals analyzing revenue quality, balance sheet leverage, and share pledging.
Financial Integrity Status:Healthy
✓ No critical accounting red flags detected in latest disclosures.
Rule-based financial pros & cons
Strengths
- Robust 3-year return on equity track record
- Consistent operating cash flow conversion
Risks
- Working capital cycle expanded slightly in recent quarters
Source: Rules applied to company filings and exchange disclosures. Data as of 7 October 2026. How this data is compiled.
Same Data For Peers
- Sun Pharmaceutical Industries Limited accounting integrity & forensics
- Divi's Laboratories Limited accounting integrity & forensics
- Torrent Pharmaceuticals Limited accounting integrity & forensics
- Zydus Lifesciences Limited accounting integrity & forensics
- Laurus Labs Limited accounting integrity & forensics
- Cipla Limited accounting integrity & forensics
Trade Aarti Pharmalabs With ATS
Track AARTIPHARM live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.